Kintor shares plunge after hair-loss drug flops in clinical trials
The company’s drug has failed to show a significant hair-boosting effect in Phase III trials, dashing investors’ hopes for a ground-breaking treatment for baldness Key Takeaways: The disappointing test results…
FAST NEWS: Nomura takes up Kintor Pharma stake
The latest: Japanese financial group Nomura Holdings disclosed it purchased 5.91 million shares of Kintor Pharmaceutical Ltd. (9939.HK) on Jun. 1, raising its stake in the biotech company from 4.06% to 5.39%,…
FAST NEWS: Kintor Pharma hits new low as loss keeps growing
The latest: Kintor Pharmaceutical Ltd. (9939.HK) announced on Thursday it did not record any revenue last year, as its net loss widened 13.3% to 954 million yuan ($139 million) from 842 million…
FAST NEWS: Kintor Pharma Strapped for Cash as Loss Widens
The latest: Kintor Pharmaceutical Ltd. (9939.HK) announced on Wednesday it did not record any revenue in the first half of the year, as its net loss widened to 518 million yuan ($75…
FAST NEWS: Kintor Pharma Soars on Good Results for Covid Drug
The latest: Kintor Pharmaceutical Ltd. (9939.HK) on Wednesday announced positive results from a Phase 3 clinical trial for its drug Proxalutamide for the treatment of mild-to-moderate ambulatory Covid-19 patients, saying…
Kintor Pharma Gets Mega-Booster from Experimental Covid-19 Drug
Company posted major milestone last week with the first emergency use authorization for its drug Proxalutamide to treat the coronavirus in Paraguay Key points: Kintor Pharma’s Proxalutamide could become a…
Recent Articles
RELATED ARTICLES
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US -
Yonghe Medical’s share repurchase gets results, but can’t hide a receding profit line
2279.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
HBM gets health boost from drug licensing deals
2142.HK
- InSilico seeks IPO boost to get AI drugs over the line
-
FAST NEWS: Nomura takes up Kintor Pharma stake
9939.HK
- HighTide Therapeutics places big IPO bet on “affluenza” drug
